Fig. 5: A view to the future. | Nature Communications

Fig. 5: A view to the future.

From: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Fig. 5

Top graphic represents the current treatment paradigm: patients with HER2+ breast cancer as determined by IHC or FISH receive the same neoadjuvant chemotherapy and HER2-directed therapy. Bottom graphic illustrates how implementation of the RPPA assay and gene expression profiling following positive IHC or FISH will enable de-escalation or escalation of chemotherapy and HER2-directed therapy. Original illustration: A. Haymond.

Back to article page